Davide Capodanno
@DFCapodanno • 22,684 subscribers
Professor of Cardiology at University of Catania, Italy. Editor-in-Chief of @EuroInterventio.
Shorts
Videos
Transcatheter mitral valve replacement (TMVR) devices that are currently undergoing clinical testing have a high anatomical screen failure rate due to challenges with annulus size or left ventricular outflow tract obstruction. The Saturn valve (InnovHeart) is a novel TMVR bioprosthesis that has a central valve mechanically connected to an annular ring. It features a low-profile design with a small footprint in the left ventricle. The annular structure and the anterior connecting arm immobilize the anterior mitral leaflet, which prevents systolic anterior motion. This is fascinating video concept comes from a study performed to assess the procedural performance and long-term healing profile of this TMVR system in healthy preclinical models.
Davide Capodanno92,088 次观看 • 2 年前
A high percentage of patients are unable to undergo a valve-in-valve TAVI procedure due to the high associated risks of sinus sequestration, coronary occlusion, or prevention of future coronary reaccess. The Splitter device, currently under testing, performs leaflet modification by creating an intentional U-shaped excision of the valve’s cusp tissue by a steerable catheter with an electrocutting wire loop running inside a cutting head that mimics alligator jaws.
Davide Capodanno26,401 次观看 • 1 年前
I have translated into slides the topics and references used by the 2025 Guidelines Task Force on valvular heart disease to justify the recommendation for TAVI in patients aged 70 years or older. Their key argument is a certain degree of pragmatism — they consider age as a surrogate for life expectancy — and the presence of a relevant proportion of patients aged 70–75 years in at least four randomized trials. I know some people who agree with this approach and others who do not.
Davide Capodanno12,450 次观看 • 8 个月前
Calcified lesions represent one of the most challenging subsets for PCI. Successful treatment is feasible in selected cases through careful planning, data integration, and expert use of available devices. Below is an algorithmic approach to the use of balloons, atherectomy, and lithotripsy.
Davide Capodanno12,726 次观看 • 1 年前
I've been thinking a lot about what the three most significant trials could be for my practice among the many presented this year at #EuroPCR. In general, I prefer it when the primary endpoint is presented for the first time. This is my selection, feel free to disagree.
Davide Capodanno19,280 次观看 • 3 年前
I reviewed the EARLY TAVR and EVOLVED studies for the Newsflash session at #PCRLV (see some slides in the attached video), contextualizing the results within the frameworks of RECOVERY, AVATAR, guidelines, meta-analyses, and, hopefully, good common sense. On the plus side, early AVR doesn't cause harm, and at some point, treatment will be necessary. Watchful waiting carries some potential risks, including a small incidence of sudden death and some degree of adverse cardiac remodeling. That said, we cannot conclusively state that early AVR is essential for every patient. Treatment decisions should take into account individual preferences and risk tolerance—some patients may fear the procedure and prefer to wait, while others may fear life without it and choose to act sooner. Ultimately, it's crucial to have an open discussion with patients about the pros and cons of early intervention versus watchful waiting. We must also assess the quality of clinical surveillance at our centers and ensure we are equipped to provide timely AVR when symptoms arise. If not, early AVR becomes a more relevant consideration.
Davide Capodanno12,243 次观看 • 1 年前
没有更多内容可加载